Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer
May 01 2020 - 4:35PM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced the appointment of
Christine Matthews as the company’s chief financial officer (CFO).
Ms. Matthews, who previously served as interim CFO, will be
responsible for leading the finance and accounting departments.
“We are pleased to appoint
Christine to the position of chief financial officer,” said Steven
Lo, president and chief executive officer of Zosano. “Christine has
demonstrated strong leadership during her tenure at Zosano and has
a proven track record of diligent financial planning and execution.
I am confident that her continued contributions will be key in our
future success as we head towards possible
commercialization.”
“It is an exciting time to
be at Zosano as we enter this next phase of growth,” said Christine
Matthews, chief financial officer of Zosano. “I look forward to
continuing my work with the Zosano management team as we prepare
for the potential approval of Qtrypta™.”
Ms. Matthews has over 20 years of broad leadership experience in
finance and accounting. She was most recently the interim CFO at
Zosano, a position she was appointed to after having served as the
company’s vice president and corporate controller. Previously, Ms.
Matthews was as an accounting and financial consultant with RGP, a
professional services company. Her past positions include senior
director of financial planning & analysis at Cepheid, a leading
molecular diagnostic company (acquired by Danaher), supporting
North America commercial operations, as well as group director of
finance at Cadence Design Systems. Ms. Matthews began her career
with Arthur Andersen, LLP. She holds a B.S. in business
administration with an emphasis in accounting from the University
of Colorado at Boulder.
About ZosanoZosano Pharma Corporation is a
clinical-stage biopharmaceutical company focused on developing
products where rapid administration of approved molecules with
established safety and efficacy profiles may provide substantial
benefit to patients, in markets where patients remain underserved
by existing therapies. The company’s intracutaneous microneedle
system technology consists of titanium microneedles coated with
drug that are designed to enable rapid systemic administration of
therapeutics to patients. Zosano’s lead product candidate is
Qtrypta™ (M207), which is a proprietary formulation of
zolmitriptan delivered via its intracutaneous microneedle system
technology, as an acute treatment for migraine. The company
anticipates that many of its current and future development
programs may enable the company to utilize a regulatory pathway
that would streamline clinical development and accelerate the path
towards commercialization.
Forward-Looking Statements This press release
contains forward-looking statements regarding the potential
approval and commercialization of Qtrypta. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict,
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the Company’s
ability to obtain additional cash resources to continue operations
for the remainder of 2020, the process of discovering, developing
and commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading "Risk Factors" in the Company's most
recent annual report on Form 10-K and quarterly reports on Form
10-Q. Although Zosano believes that the expectations reflected in
these forward-looking statements are reasonable, Zosano cannot in
any way guarantee that the future results, level of activity,
performance or events and circumstances reflected in
forward-looking statements will be achieved or occur. All
forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contact: Christine Matthews Chief
Financial Officer (510) 745-1200
PR Contacts: Sylvia Wheeler
swheeler@wheelhouselsa.com
Alexandra Santos asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024